(The author is a Reuters Breakingviews columnist. The opinions
expressed are her own.)
By Sharon Lam
HONG KONG, July 13 (Reuters Breakingviews) - The Japanese
drugmaker is near a deal that would get it to a $10 bln
divestiture target 18 months after buying its Irish rival for
$62 bln. Promised cost savings are materialising and debt slowly
shrinking. Weak stock performance under boss Christophe Weber
suggests he overpaid.
Full view will be published shortly.
On Twitter https://twitter.com/sharonlamhk
CONTEXT NEWS
- - Taisho Pharmaceutical and buyout firms Blackstone and
Bain Capital are among the final bidders for Takeda
Pharmaceutical’s consumer business in Japan, a deal that could
be worth up to 400 billion yen ($3.7 billion), Reuters reported
on June 19, citing unnamed sources. Takeda has not confirmed the
media reports.
- For previous columns by the author, Reuters customers can
click on LAM/
- SIGN UP FOR BREAKINGVIEWS EMAIL ALERTS: http://bit.ly/BVsubscribe
<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Reuters: Blackstone, Taisho Pharma among final bidders for
Takeda's Japan OTC unit – sources urn:newsml:reuters.com:*:nL4N2DW1JR
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
(Editing by Jeffrey Goldfarb and Jamie Lo)
((sharon.lam@thomsonreuters.com; Reuters Messaging:
sharon.lam.thomsonreuters.com@reuters.net))